Merck ( MRK) and Pfizer ( PFE) have rediscovered their past glory, Jim Cramer said on CNBC's "Stop Trading!" segment Thursday.

"When people look at this earnings period, they're seeing a sea change in the market," Cramer said. "Merck and Pfizer were the bluest of the blues from 1985 to about 1998. This is what people want to own again." Cramer said money is flowing out of the railroad and tech sector and into Merck and Pfizer, which are "rolling higher without any resistance."

Coca-Cola ( KO) is another big 1990s performer on its way back. "People have decided that CEO Neville Isdell is doing a great job" and "don't care that it sells at 20 times earnings."

Regarding the Justice Department complaint against Bristol-Myers ( BMY) and Sanofi ( SNY), Cramer was skeptical. "This is like when Bobby Kennedy sat people down in a room and said, 'We know you're fixing prices. We're going to put you in jail.'" Cramer said the one problem with Bristol/Sanofi is that "the price hasn't been fixed yet."

Cramer also took note of Comcast's ( CMCSA) big quarter and said it's evidence that the battle for broadband isn't a zero-sum game. "Adoption is happening fast enough that both AT&T ( T) and Comcast are winning. Nobody thought that could happen, particularly the hedge funds shorting the stocks."

At the time of publication, Cramer was long Bristol-Myers.

Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for Action Alerts PLUS. Listen to Cramer's RealMoney Radio show on your computer; just click here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click here to get his second book, "You Got Screwed!" and click here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by clicking here.

TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says